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Background: Astrocyte elevated gene-1(AEG-1) plays an important role in the development and progression of
certain types of human cancers. However, the expression dynamics of AEG-1 in cervical cancer and its clinical/prognostic
significance are unclear.
Method: In present study, the methods of tissue microarrays (TMA) and immunohistochemistry (IHC) were utilized to
investigate AEG-1 expression in cervical intraepithelial neoplasia (CIN) and cervical cancer. Receiver operating characteristic
(ROC) curve analysis, χ2 test, Kaplan-Meier plots, and multivariate Cox regression analysis were used to analyze the data.
Results: The expression level of AEG-1 was increased from CIN I to CIN III. High expression of AEG-1 could be observed in
61.1% (55/90) of cervical cancer. Moreover, high expression of AEG-1 correlated with tumor size and lymph node
metastasis (all P <0.05). More importantly, high expression of AEG-1 was closely associated with cervical cancer
patient shortened survival time as evidenced by univariate and multivariate analysis (P <0.05).
Conclusions: Our data suggest for the first time that high expression of AEG-1 is associated significantly with
progression of cervical cancer. AEG-1 overexpression, as examined by IHC, has the potential to be used as an
immunomarker to predict prognosis of cervical cancer patients.
Keywords: AEG-1, Cervical cancer, Tissue microarrays, PrognosisBackground
Cervical cancer is the second most frequent cancer in
women. Cervical lesions advance from cervical intraepithe-
lial neoplasia (CIN) to cervical cancer is a complicated
process initiated by persistent infection with high-risk hu-
man papillomavirus (HPV) [1]. Currently, therapies include
operation combined with chemotherapy and radiotherapy
are major treatment means of the cervical cancer. How-
ever, these treatment methods are effective only in limited
cases. Therefore, it is of great value to better understanding
of molecular events and prognostic markers as well as
novel therapeutic strategies of cervical cancer.
Astrocyte elevated gene-1(AEG-1) was originally iden-
tified as a human immunodeficiency virus-1 (HIV-1)-* Correspondence: mengyuanguang1@126.com
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reproduction in any medium, provided the orinducible gene in human fetal astrocytes [2]. Recently,
numerous studies have shown the key role of AEG-1 in
the development and progression of cancer [3,4]. Aber-
rant elevation of AEG-1 expression occurs in a series of
human cancers, such as gastric cancer, breast cancer,
osteosarcoma, non-small cell lung cancer, and colon
cancer, compared to the matched non-neoplastic regions
[5-9]. AEG-1 was found to promote the proliferation of
breast cancer cells by downregulating FOXO1 through
the PI3K/AKT signaling pathway [10]. Interestingly, in
HeLa cells, overexpression of AEG-1 significantly en-
hances the invasive ability of cells, while inhibition of
AEG-1-induced NF-κB decreases invasion [11]. Further-
more, AEG-1 has been found to upregulate MMP-9 and
induce human glioma cell invasion [12]. These reports
suggest that the AEG-1 might be involved in the pro-
gression of multiple cancers.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Relationship between AEG-1 expression and
clinical parameters in cervical cancer patients
Clinical parameter Case AEG-1 expression P value
Low High
Age (years)
<50 35 15 20
≥50 55 20 35 0.658
Tumor size (cm)
<4 63 30 33
≥4 27 5 22 0.010a
Histological classification
Squamous carcinoma 74 26 48
Adenocarcinoma 16 9 7 0.158
Clinical stage
I + II 53 17 36
III + IV 37 18 19 0.129
Pathological grade
G1 19 10 9
G2+ G3 71 25 46 0.192
Lymph node metastasis
Absent 52 27 25
Present 38 8 30 0.004a
a < 0.05.
Figure 1 Immunohistochemical analysis of AEG-1 in normal cervical squ
staining was detected in the normal cervical squamous epithelium. Immunor
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ation between AEG-1 expression and progression of cer-
vical intraepithelial neoplasia or patient survival in cervical
cancer. Therefore, in the present study, we evaluated
AEG-1 protein expression in CIN and cervical cancer
patient samples to investigate its role in cervical le-
sions, and its correlation with clinicopathological variables.
Methods
Patients and tissue specimens
A total of 90 unselected cervical cancer samples were
collected between 1999 and 2001 from the Department
of Pathology, Chinese PLA General Hospital. The tumor
cases included 74 cases of squamous carcinoma and 16
cases of adenocarcinoma. Moreover, cases of CIN I, CIN
II, and CIN III were 18, 17, and 15 respectively. Hystero-
myoma as normal control cervical tissues (n = 10) that
obtained from surgically removed uteruses. Ages of the
90 patients with cervical cancer ranged from 30 to
65 years (mean, 48.1 years). Clinicopathological charac-
teristics of the tumor cases are presented in Table 1. The
Institute Research Medical Ethics Committee of Chinese
PLA General Hospital granted approval for this study.
Tissue microarrays (TMA) construction and
immunohistochemistry
Tissue microarray was constructed as the method de-
scribed previously [13]. Briefly, the paraffin-embeddedamous epithelium (A), CIN I (B), CIN II (C), and CIN III (D). No AEG-1
eactivity of AEG-1 gradually increased from CIN I, CIN II, to CIN III.
Figure 2 The expression of AEG-1 in cervical cancer. Positive expression of AEG-1 in squamous carcinoma (A) and adenocarcinoma
(B). (C, D) Negative controls (200×).
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stained slides were overlaid for tissue TMA sample.
Triplicate 0.6 mm diameter cylinders were punched
from representative areas of an individual donor tissue
block, and re-embedded into a recipient paraffin block
at a defined position, using a tissue arraying instru-
ment (Beecher Instruments, Silver Spring, MD, USA).
The TMA blocks were cut into 4-μm sections and
deparaffinized by routine techniques. First, the slides
were microwaved in 10 mM citrate buffer (pH 6.0) for
10 min. Then the slides were incubated with anti-AEG-1
(ab76742, 1:100 dilution, Abcam, UK) and stored over-
night at 4°C. The slides were sequentially incubated withFigure 3 Immunohistochemistry of AEG-1 in cervical cancer tissue mi
carcinoma (A, B, C, D) and adenocarcinoma (E) (100×). The lower panels in
the upper panels (F, G, H, I, J).a secondary antibody (Maxim-Bio, Fuzhou, China). Label-
ing was detected by adding diaminobenzidine (Maxim-Bio).
Sections were then counterstained with hematoxylin. A
negative control was obtained by replacing the primary
antibody with a normal murine IgG.
Evaluation by immunohistochemistry
Immunoreactivity for AEG-1 protein was scored using a
semi-quantitative method by evaluating the number of
positive tumor cells over the total number of tumor cells.
Scores were assigned by using 5% increments (0%, 5%,
10%,… 100%). Expression for AEG-1 was assessed by two
independent pathologists.croarray (TMA). High expression of AEG-1 was observed in squamous
dicated the higher magnification (200×) from the area of the box in
Figure 4 Receiver operating characteristic curve analysis was employed to determine the cutoff score for the high expression of
AEG-1. The sensitivity and specificity for each outcome were plotted: (A) Tumor size, (B) lymph node metastasis, (C) pathological grade,
(D) clinical stage.
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Receiver operating characteristic (ROC) curve analysis
was performed to determine cutoff score for tumor ‘high
expression’ by using the 0,1-criterion [14]. At AEG-1
score, the sensitivity and specificity for each outcome
under study was plotted, thus generating various ROC
curves. The score was selected as the cutoff value which
was closest to the point with both maximum sensitivity
and specificity. Tumors designated as low expression of
AEG-1 were those with the scores below or equal to the
cutoff value, while tumors of high expression were those
with scores above the value. To use ROC curve analysis,
the clinicopathologic characteristics were dichotomized:
tumor size (<4 cm vs. ≥4 cm), pathological grade (G1 vs.
G2 + G3), clinical stage (I + II vs. III + IV), lymph node
metastasis (Yes vs. No).Table 2 Area under the curve (AUC) of receiver operating
characteristic curve for each clinicopathologic feature
Variable AUC (95% CI) P value
Tumor size 0.826 (0.811-0.842) 0.000
Pathological grade 0.598 (0.578-0.619) 0.002
Clinical stage 0.478 (0.456-0.501) 0.046
Lymph node metastasis 0.745 (0.728-0.763) 0.000Statistical analysis
Statistical analysis was performed by using the SPSS stat-
istical software package (standard version 17.0; SPSS,
Chicago, IL, USA). ROC curve analysis was applied to
determine the cutoff score for high expression of AEG-1.
The associations between AEG-1 expression and other
variables were analyzed by using χ2 test. For univariate
survival analysis, survival curves were obtained with the
Kaplan-Meier method. P <0.05 denotes the presence of a
statistically significant difference.Results
AEG-1 is upregulated from CIN I to CIN III
Figure 1 show AEG-1 expression is related to the grade
of the lesion in CIN. Expression of AEG-1 was not de-
tected in normal squamous epithelium. Of the 50 CIN
lesions, 11 of 15 (73.3%) CIN III were AEG-1 positive, in
contrast with only 16.7% (3/18) and 35.3% (6/17) in CIN
I and CIN II, respectively. Therefore, a close relationship
was observed between the increasing grade of lesion and
the intensity of AEG-1 staining in CIN.Expression patterns of AEG-1 in cervical cancer
For AEG-1 IHC staining in cervical cancer, immunore-
activity was primarily observed in the cytoplasm of
tumor cells (Figures 2 and 3). AEG-1 expression was
evaluated informatively in 90 cervical cancers by the
TMA constructed previously. The non-informative five
TMA samples included samples with too few tumor cells
Table 3 Univariate and multivariate analysis of overall survival in patients with cervical cancer
Factor Univariate analysis Multivariate analysis
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Age (years) 1.021 0.981-1.052 0.543
Tumor size 1.678 0.872-3.626 0.257
Histological classification 0.874 0.258-2.962 0.870
Clinical stage 6.783 2.345-18.926 0.001 4.677 1. 535–9.794 0.018
Pathological grade 1.467 0.791-3.345 0.342
Lymph node metastasis 0.108 0.024-0.542 0.002 0.181 0.032-0.642 0.019
AEG-1 high expression 5.894 2.590-18.268 0.004 4.021 1.734-8.283 0.027
Figure 5 Kaplan-Meier analysis of overall survival curves of
cervical cancer patients according to AEG-1 expression. The
cervical cancer patients with high expression of AEG-1 showed
significantly lower overall survival rate than those with low expression
of AEG-1.
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tissue slides. According to ROC curve analysis, expres-
sion percentage for AEG-1 above the cutoff value, 40%
was regarded as high expression while below the cutoff
value was considered as low expression. In the present
study, high expression of AEG-1 could be detected in
61.1% (55/90) of cervical cancers. Thirty-five of the 90
(38.9%) cervical cancer samples showed low staining of
AEG-1. As shown in Figures 2 and 3, AEG-1 immunore-
activity was predominantly expressed in the cytoplasm
of tumor cells. Furthermore, our results suggest that
AEG-1 staining from normal cervical specimens, CINs,
to cervical cancer was enhanced gradually.
Selection of cutoff scores for high AEG-1 expression
To identify an optimal cutoff value for high expression,
ROC curve analysis was used to determine the cutoff
score for expression of AEG-1 in various patterns. The
ROC for each clinicopathological parameter (Figure 4)
clearly show the point on the curve closest to (0.0, 1.0)
which maximizes both sensitivity and specificity for the
outcome. Tumors with scores above the obtained cutoff
value were considered as high expression of AEG-1 pro-
tein leading to the greatest number of tumors correctly
classified as having or not having the clinical outcome.
The corresponding area under the curve (AUC) and cut-
off scores were gathered and shown in Figure 4 and
Table 2, respectively. In the present study, tumor size
had the shortest distance from the curve to the point
(0.0, 1.0), and we selected the cutoff value determined
by tumor size. Therefore, the cutoff score for high ex-
pression of AEG-1 was defined when >40% of cancer
cells had positive staining of AEG-1.
Increased AEG-1 expression correlates with clinicopathologic
features of cervical cancer
The high expression rates of AEG-1 in cervical cancer
with respect to several clinicopathologic features are pre-
sented in previous table. The high AEG-1 expression was
significantly correlated with larger tumor size (P = 0.010)
and lymph node metastasis (P = 0.004). There was nosignificant correlation between AEG-1 expression and
other clinicopathologic features, such as patient age,
pathological grade, and clinical stage.
High AEG-1 expression is associated with poor prognosis
of patients with cervical cancer
Finally, we detected the value of AEG-1 expression as a
predictor of disease outcome in patients with cervical
cancer. Assessment of survival in total cervical cancer
patients revealed that high expression of AEG-1 was cor-
related with poor prognosis compared with low cases.
Univariate Cox regression analysis suggested that AEG-1
expression, clinical stage, and lymph node metastasis
were significantly associated with overall survival. Since
features observed to have a prognostic influence by uni-
variate analysis may covariate, AEG-1 expression and
those clinicopathologic variables that were significant in
univariate analysis were further examined in multivariate
analysis (Table 3). Results indicated that high AEG-1 ex-
pression was an independent prognostic factor for poor
patient overall survival (hazard ratio, 4.021; 95%CI,
1.734-8.283, P = 0.027; Table 3). Clinical stage and lymph
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patient survival (both P <0.05). Of all clinicopathologic
features, clinical stage was the most independent para-
meter predicting prognosis (P = 0.018).
To elucidate the prognostic role of AEG-1 in cervical
cancer patients, overall survival rates was estimated by
Kaplan-Meier survival curves. Patients with high expres-
sion of AEG-1 had shorter overall survival period than
those with low expression (P <0.05) (Figure 5).
Discussion
Recent studies have indicated overexpression of AEG-1
as an important event in a series of cancer. Aberrant
AEG-1 expression has been found in some solid tumors
including prostateand hepatocellular carcinoma [15,16].
Additionally, AEG-1 expression is increased with the
clinical staging of neuroblastoma [17]. Furthermore,
AEG-1 expression may represent an independent bio-
marker for the prediction of prognosis of neuroblastoma
and salivary gland carcinoma [18].
Although the important roles of AEG-1 in tumor pro-
gression in multiple cancers are now being clarified, its
function in development of cervical cancer remains un-
clear. In the present study, we evaluated the possibility
of AEG-1 as a therapeutic target of cervical cancer. We
presented the first evidence of AEG-1 upregulation from
CIN I to CIN III. Moreover, AEG-1 protein was ob-
served in 61.1% of cervical cancer samples, and AEG-1
expression was found to be significantly correlated with
tumor size and lymph node metastasis, as well as un-
favorable prognosis of cervical cancer patients. Similarly,
Zhang et al. found that 180 of 200 (90%) cervical carcin-
oma tissue specimens exhibited positive staining for
AEG-1 and the upregulation of AEG-1 was significantly
correlated with the clinical staging of the patients [19].
These data indicated the important role of AEG-1 in the
progression of cervical cancer.
Overexpression of AEG-1 was considered to markedly
promote proliferation and tumorigenicity in breast can-
cer cells, however, an AEG-1-knockdown cell model
inhibited cell proliferation and the colony-forming ability
[10]. AEG-1 was found to promote the proliferation of
various types of cancer cells by activating the PI3K/AKT
and NF-κB signaling pathways [20]. Moreover, it was re-
ported that AEG-1 promotes degradation BCCIPα [21].
BCCIPαwas a tumor suppressor and could inhibit
growth of cancer cells. Our result also demonstrated up-
regulation of AEG-1 was correlated with larger tumor
size and validated that AEG-1 maybe participated in
proliferation of cancer cells.
The metastasis-promoting role of AEG-1 has been
confirmed using xenograft model of breast cancer metas-
tasis. In this model, AEG-1 was found to not only pro-
mote lung metastasis, but also increase bone metastasis.Conversely, siRNA-silencing of AEG-1 efficiently reduced
lung metastasis of cancer cells [22]. Our findings revealed
AEG-1 overexpression was associated with lymph node
metastasis. As mentioned above, the PI3K/AKT and NF-κB
or other signaling pathways maybe involved in lymph node
metastasis. However, the molecular mechanism of AEG-1
promotes lymph node metastasis of cancer cells remains
unknown and need further elucidated. Furthermore, we
found AEG-1 overexpression was correlated with poor
prognosis and reduced survival of patients with cervical
cancer. Multivariate analysis showed that AEG-1 could
be used as an independent prognostic predictor for cer-
vical cancer patients.
Conclusions
In conclusion, a key finding of the present study is that
up regulation of AEG-1 is correlated with tumor growth
and lymph node metastasis. Moreover, AEG-1 staining is
related to the increasing grade of the lesion in CIN. Al-
though further studies are needed to clarify the role and
mechanism of AEG-1 upregulation in the progression of
cervical cancer, the present study will provide new in-
sights into the progression of cervical cancers.
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